Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

The Jenner Institute is conducting a new study, using BCG, the current licensed vaccine against tuberculosis. In this study, they will give BCG a second time to people who have already had BCG once before, and will compare whether giving it by inhalation is better at protecting people against tuberculosis than giving it into the skin

Young man with using the inhaler with a peg in his nose

As the natural route of infection with tuberculosis is through inhalation of droplets into the lungs, this study, which delivers BCG by the same route, is hoped to be better at stimulating the immune system.

Prof Helen McShane Chief Investigator, TB Vaccine Trials Jenner Institute, University of Oxford, said:

'TB kills more people than any other infectious disease and we urgently need better vaccines. This important new study will help us to see whether giving BCG more than once stimulates a stronger immune response and whether giving it by inhalation is better than giving it into the skin. Small studies like these are really important to help us understand the immune response in people and allow us to design and test better vaccines.

This study will also explore whether giving people with Type 2 Diabetes BCG in the skin stimulates as strong an immune response as giving BCG in the skin to healthy people without diabetes. We know that people with type 2 diabetes are more likely to get TB and part of this may be because the BCG vaccine does not work as well in this group.'


Read the full story on the University of Oxford website.

Similar stories

New small molecule found to suppress the evolution of antibiotic resistance in bacteria

Researchers from the Ineos Oxford Institute for antimicrobial research (IOI) and the Department of Pharmacology at Oxford University, have developed a new small molecule that can suppress the evolution of antibiotic resistance in bacteria and make resistant bacteria more susceptible to antibiotics.